Samyang Biopharm is specialized in commercialization of first generics and drug delivery system (DDS)-based modified drugs for cancer tratment and development of small-molecule drugs, new biologic drugs, and cancer virus vaccines.
Samyang Biopharm is exporting its oncology products to more than 25 countries and its cytotoxic manufacturing facility is authorized by authorities from Korea, Europe, and Japan. To expand its Contract Development & Manufacturing, Samyang Biopharm is constructing a new facility which is expected to achieve full cGMP operation and the construction will be completed in 2020. Furthermore, it continues to enhance its product portfolio to meet the latest pharmaceutical trends.
In October, 2018, it established Samyang Biopharm USA Inc. in Cambridge, USA and drives to enter into U.S market mainly for pharmaceutical developmentof immune-oncology and rare diseases.
Samyang Biopharm manufactures Cytotoxic APis, Cytotoxic Injections, Transdermal Patches, and offers CDMO services.
If you would like to know more about Samyang, click "request info" or click brochures and videos.
Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Africa; Central America (e.g. Mexico); East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore)
Categories affiliated with Samyang Biopharmaceuticals Corp
Are you a supplier?
Here's what CPhI Online can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation